Boston Scientific Says Japan Approved Farapulse Pulsed Field Ablation System

MT Newswires Live09-27 19:35

Boston Scientific (BSX) said Friday it has received approval for its Farapulse pulsed field ablation system from Japan's Pharmaceuticals and Medical Device Agency.

The Farapulse system is indicated to isolate pulmonary veins to treat paroxysmal atrial fibrillation, the company added.

The system uses non-thermal electrical fields to ablate cardiac tissue associated with atrial fibrillation, Boston Scientific said.

The company intends to roll out the Farapulse system in Japan in the coming weeks.

Boston Scientific also said it anticipates starting the Option-A clinical study in China, Hong Kong, Japan, and Taiwan early next year to evaluate the safety and efficacy of concomitant processes using the Farapulse system for cardiac ablation.

Price: 83.38, Change: +0.30, Percent Change: +0.36

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment